These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 16286123

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
    Lipton A, Zheng M, Seaman J.
    Cancer; 2003 Sep 01; 98(5):962-9. PubMed ID: 12942563
    [Abstract] [Full Text] [Related]

  • 26. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 01; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
    Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J.
    Cancer; 2004 Jun 15; 100(12):2613-21. PubMed ID: 15197804
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.
    Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.
    J Urol; 2006 May 15; 175(5):1679-83; discussion 1683. PubMed ID: 16600728
    [Abstract] [Full Text] [Related]

  • 33. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
    Ishizaka K, Machida T, Kobayashi S, Kanbe N, Kitahara S, Yoshida K.
    Int J Urol; 2007 Dec 15; 14(12):1071-5. PubMed ID: 18036042
    [Abstract] [Full Text] [Related]

  • 34. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
    Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R.
    J Clin Oncol; 2005 Aug 01; 23(22):4925-35. PubMed ID: 15983391
    [Abstract] [Full Text] [Related]

  • 35. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.
    Saad F.
    Semin Oncol; 2002 Dec 01; 29(6 Suppl 21):19-27. PubMed ID: 12584691
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.
    Saad F, Eastham J.
    Urology; 2010 Nov 01; 76(5):1175-81. PubMed ID: 21056263
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.
    Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M, Harsoulis F.
    Ann Hematol; 2007 Jan 01; 86(1):23-30. PubMed ID: 17013645
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.